The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase (EVALUATE)

D

Dr. Soetomo General Hospital

Status

Unknown

Conditions

Non-Small-Cell Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT02755337
Dr. Soetomo General Hospital

Details and patient eligibility

About

To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.

Full description

Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation. Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib. Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.

Enrollment

70 estimated patients

Sex

All

Ages

16 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • NSCLC based on histopathologic examination
  • Adenocarcinoma and/or nonadenocarcinoma based on histology examination
  • Clinical stadium stage IIIB and IV
  • Age 16-70 years old
  • Received gefitinib as therapy
  • At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015

Exclusion criteria

Missing data of any variables of the treatment outcomes in the medical record

Trial contacts and locations

1

Loading...

Central trial contact

Anna Febriani, MD; Laksmi Wulandari, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems